Combinação de medicamentos resfria o corpo para limitar danos de AVC

Dois medicamentos já existentes reduziram a temperatura corporal central em animais após um AVC e diminuíram as lesões cerebrais. Um pequeno estudo com humanos mostrou efeitos limitados devido à administração lenta. Os pesquisadores agora planejam um novo estudo com infusões mais rápidas.

Pesquisadores testaram prometazina e clorpromazina em camundongos e macacos rhesus após induzirem AVCs. Os medicamentos reduziram a temperatura corporal, diminuíram o metabolismo da glicose nas células e reduziram os danos cerebrais. Os macacos tratados também apresentaram melhora na função dos membros.

Em um ensaio clínico com 32 pessoas, os mesmos medicamentos reduziram a temperatura em apenas 0,3°C e não diminuíram os danos do AVC. A equipe atribuiu isso a infusões lentas de 12 horas, que falharam em atingir níveis eficazes da droga rapidamente.

Os medicamentos, já aprovados para febre do feno e psicose, atuam no sistema nervoso central sem causar tremores. Um novo estudo testará infusões de uma hora para determinar se o resfriamento mais rápido melhora os resultados.

Artigos relacionados

A woman undergoing chemotherapy performs home exercises in her living room to ease chemo brain symptoms.
Imagem gerada por IA

Home-based exercise program may ease “chemo brain” symptoms during chemotherapy, Phase II trial suggests

Reportado por IA Imagem gerada por IA Verificado

A Phase II randomized trial found that a six-week, home-based walking and resistance program improved attention test performance and reduced reports that others noticed cognitive problems among patients receiving chemotherapy. Low-dose ibuprofen improved some attention measures but showed mixed results on memory outcomes. The study was published in Cancer.

Researchers at the University of Hong Kong have developed a world-first nasal spray that delivers neurotherapeutic powder directly to the brain as first aid for ischemic stroke patients. The treatment, named NanoPowder, is designed to reduce brain damage by more than 80 per cent and improve stroke survival rates. Clinical trials are expected by 2030.

Reportado por IA

A widely studied anti-aging treatment triggered significant brain damage in mice, according to new research from the University of Connecticut. The drug combination dasatinib plus quercetin caused myelin loss and changes resembling those seen in multiple sclerosis. The findings raise questions about its use in longevity studies and off-label therapies.

Researchers at Texas A&M University have developed a nasal spray that appears to reverse aspects of brain aging after just two doses. The treatment reduced inflammation and restored memory function in models for months afterward. The findings were published in the Journal of Extracellular Vesicles.

Reportado por IA Verificado

Researchers at Scripps Research say an experimental vaccine kept fentanyl and several related designer opioids from reaching the brain in mouse studies, potentially offering a way to blunt overdose effects before they begin.

An experimental therapy called VERVE-102 lowered LDL cholesterol by up to 62 percent after a single dose in an early safety study. The results come from a Phase I trial involving 35 patients with high cholesterol or early cardiovascular disease. Data were published this week in the New England Journal of Medicine.

Reportado por IA

Therabody has introduced the CryoTherm Palm, a compact handheld device that provides both cooling and heating therapy for athletes and fitness enthusiasts. The three-in-one tool is designed to aid recovery during workouts through palm cooling technology.

Este site usa cookies

Usamos cookies para análise para melhorar nosso site. Leia nossa política de privacidade para mais informações.
Recusar